XML 38 R16.htm IDEA: XBRL DOCUMENT
v3.24.3

Financial Instruments | 9 Months Ended
--- | ---
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract] |
Financial Instruments | The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:
(In millions) |  | As of September 30, 2024 |  | As of December 31, 2023
Money market funds |  | $ | 802.4 |  |  | $ | 610.7 |
Total |  | $ | 802.4 |  |  | $ | 610.7 |
The carrying value of our money market funds approximates fair value due to their short-term maturities. Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable equity securities, classified as available-for-sale:
|  | As of September 30, 2024
(In millions) |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
Marketable equity securities |  |  |  |  |  |  |  |
Marketable equity securities, current |  | $ | 58.3 |  |  | $ | — |  |  | $ | (8.2) |  |  | $ | 50.1 |
Marketable equity securities, non-current |  | 676.0 |  |  | — |  |  | (421.4) |  |  | 254.6 |
Total marketable equity securities |  | $ | 734.3 |  |  | $ | — |  |  | $ | (429.6) |  |  | $ | 304.7 |
|  | As of December 31, 2023
(In millions) |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
Marketable equity securities |  |  |  |  |  |  |  |
Marketable equity securities, current |  | $ | 31.6 |  |  | $ | — |  |  | $ | (21.0) |  |  | $ | 10.6 |
Marketable equity securities, non-current |  | 948.3 |  |  | — |  |  | (542.1) |  |  | 406.2 |
Total marketable equity securities |  | $ | 979.9 |  |  | $ | — |  |  | $ | (563.1) |  |  | $ | 416.8 |
Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
(In millions) |  |  |  | For the Three Months Ended September 30, 2023 |  |  |  | For the Nine Months Ended September 30, 2023
Proceeds from maturities and sales |  |  |  | $ | 5,698.6 |  |  |  |  | $ | 7,380.8 |
Realized gains |  |  |  | 1.0 |  |  |  |  | 1.4 |
Realized losses |  |  |  | 16.3 |  |  |  |  | 18.4 |
We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read Note 2, Acquisitions, to these condensed consolidated financial statements. Realized losses for the three and nine months ended September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds. Strategic Investments Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 8, Fair Value Measurements, to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. As of September 30, 2024 and December 31, 2023, our strategic investment portfolio was comprised of investments totaling $353.3 million and $460.7 million, respectively, which are included in other current assets and investments and other assets within our condensed consolidated balance sheets. The decrease in our strategic investment portfolio as of September 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock, partially offset by an increase in the fair value of our investment in Denali common stock. Additionally, we sold a portion of our Denali and Sangamo common stock during 2024. For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2023 Form 10-K.

X
- Definition The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details
Name: | us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration